Compare AstraZeneca plc (AZN) vs Herbalife Nutrition Ltd (HLF) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Herbalife (HLF) trades at $13.10, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 77.78% gross margin and attractive valuation metrics including a P/E of 5.75 and P/S of 0.27. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, while the company completed a $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.

The outlook remains positive with analyst consensus favoring Buy ratings (57.69%) and improving debt-to-asset ratios from 82.84% in 2024 to 71.67% in 2025. Key risks include high leverage, competitive pressures in the nutrition space, and regional market volatility. The stock offers value appeal given low multiples and recent strategic initiatives to expand digital health offerings.